A screening test for renovascular hypertension by means of orally active angiotensin I converting enzyme inhibitor, captopril (SQ 14225).
Orally active converting enzyme inhibitor (Captopril, SQ 14225) was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II) and 8 renovascular hypertensive patients (Group III). In Group III, 5 of 8 patients had control plasma renin activity (PRA) similar to those in Group I and II patients, but the PRA response to the administration of Captopril was greater in 7 of 8 patients than that in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.
D002216:Captopril; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000175:diagnosis*; D006978:Hypertension, Renovascular / Q000175:diagnosis*; D008297:Male; D011392:Proline / Q000031:analogs & derivatives*; D012083:Renin / Q000097:blood
D011392:Proline; D002216:Captopril; D012083:Renin